The World Health Organisation (WHO), in its first global guidelines on Glucagon-Like Peptide-1 (GLP-1) therapies for obesity, has said these drugs must be used alongside intensive behavioural ...
WHO issues conditional guidance on GLP‑1 therapies for obesity, calling for wider access amid high prices, safety questions & ...